



NDA 20-533/S-014

Abraxis BioScience, Inc.  
Riverway One  
6133 N. River Road, Suite 500  
Rosemont, IL 60018-5172

Attention: Dale Carlson  
Associate Director, Regulatory Affairs

Dear Mr. Carlson:

Please refer to your supplemental new drug application dated May 11, 2006, received May 12, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Naropin® (ropivacaine HCl) Injection.

This “Changes Being Effected” supplemental new drug application provides for changes to the **WARNINGS** and **MANAGEMENT OF LOCAL ANESTHETIC EMERGENCIES** sections of the package insert.

We have completed our review of this application, and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling text for the package insert.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 20-533/S-014.**" Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH  
Food and Drug Administration  
WO 22, Room 4447  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Allison Meyer, Regulatory Project Manager, at (301) 796-1258.

Sincerely,

*{See appended electronic signature page}*

Bob Rappaport, MD  
Director  
Division of Anesthesia, Analgesia and  
Rheumatology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Bob Rappaport  
8/8/2006 01:53:56 PM